Literature DB >> 12134955

Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.

Linda M Hiebert1, Sandra M Wice, Tidly Ping, Ronald E Hileman, Tfilay Polat, Robert J Linhardt.   

Abstract

PURPOSE: Aluminum sucrose octasulfate (SOS) is used clinically to prevent ulcers. Under physiologic conditions, the sodium salt of this drug can be formed. Our objective was to determine whether sodium SOS was absorbed when administered orally. In addition to furthering our understanding of aluminum SOS, this study also aimed to clarify how other polyanionic drugs, such as heparin and low-molecular-weight heparins, are absorbed.
METHODS: [14C]-labeled and cold sodium SOS (60 mg/kg) were given to rats by stomach tube. Radioactivity was counted in gut tissue, gut washes, and nongut tissue (i.e., lung, liver, kidney, spleen, endothelial, and plasma samples) at 3 min, 6 min, 15 min, 30 min, 60 min, 4 h, and 24 h, and in urine and feces accumulated over 4 h and 24 h.
RESULTS: Peak radioactivity was found in the tissue and washes of the stomach, ileum, and colon at 6 min, 60 min, and 4 h, respectively, showing progression through the gut. Gut recovery accounted for 84% of the dose at 6 min but only 12% of the dose at 24 h, including counts from feces. Radioactivity was recovered from nongut tissue (averaging 8.6% of the dose) and accumulated urine (18% of the dose at 24 h). When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively).
CONCLUSIONS: Results indicate that sodium SOS is absorbed, agreeing with previous studies demonstrating the oral absorption of other sulfated polyanions. Endothelial concentrations must be considered when assessing the pharmacokinetics of these compounds. The measured plasma drug concentrations reflect the much greater amounts of drug residing with the endothelium.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134955     DOI: 10.1023/a:1016161001013

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease.

Authors:  M Lunetta; T Salanitri
Journal:  J Int Med Res       Date:  1992-02       Impact factor: 1.671

2.  Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate.

Authors:  S Szabo; P Vattay; E Scarbrough; J Folkman
Journal:  Am J Med       Date:  1991-08-08       Impact factor: 4.965

3.  Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate.

Authors:  S O Canapp; R M McLaughlin; J J Hoskinson; J K Roush; M D Butine
Journal:  Am J Vet Res       Date:  1999-12       Impact factor: 1.156

Review 4.  Pharmacological actions of sulodexide.

Authors:  F A Ofosu
Journal:  Semin Thromb Hemost       Date:  1998       Impact factor: 4.180

5.  Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.

Authors:  L M Hiebert; S M Wice; T Ping; D Herr; V Laux
Journal:  Thromb Haemost       Date:  2001-01       Impact factor: 5.249

6.  The oral bioavailability of pentosan polysulphate sodium in healthy volunteers.

Authors:  R A Faaij; N Srivastava; J M van Griensven; R C Schoemaker; C Kluft; J Burggraaf; A F Cohen
Journal:  Eur J Clin Pharmacol       Date:  1999-02       Impact factor: 2.953

7.  Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial.

Authors:  J C Nickel; B Johnston; J Downey; J Barkin; P Pommerville; M Gregoire; E Ramsey
Journal:  Urology       Date:  2000-09-01       Impact factor: 2.649

8.  Emerging anticoagulant and thrombolytic drugs.

Authors:  O Iqbal; S Aziz; D A Hoppensteadt; S Ahmad; J M Walenga; M Bakhos; J Fareed
Journal:  Expert Opin Emerg Drugs       Date:  2001-04       Impact factor: 4.191

9.  Antithrombotic activity of oral unfractionated heparin.

Authors:  L M Hiebert; S M Wice; L B Jaques
Journal:  J Cardiovasc Pharmacol       Date:  1996-07       Impact factor: 3.105

Review 10.  Stress ulcer prophylaxis. Do critically ill patients need it?

Authors:  J L DePriest
Journal:  Postgrad Med       Date:  1995-10       Impact factor: 3.840

View more
  2 in total

1.  Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Authors:  Suryakala Sarilla; Sally Y Habib; Dmitri V Kravtsov; Anton Matafonov; David Gailani; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

2.  Movement of heparins across rat gastric mucosa is dependent on molecular weight and pH.

Authors:  Bita Moazed; Linda M Hiebert
Journal:  Pharm Res       Date:  2008-10-21       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.